Q-omics provides the consensus-scored DGAT2L6 profile across patient tissues and cancer cell-line models. DGAT2L6 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, DGAT2L6 is differentially expressed in 7, with the highest sampling consensus in THCA. Additionally, DGAT2L6 RNA expression shows 14,524 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight SCLC, THCA, and TGCT as cancer lineages where DGAT2L6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DGAT2L6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DGAT2L6 survival associations across molecular data types. DGAT2L6 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DGAT2L6 RNA expression–survival associations across cancer types. High DGAT2L6 expression shows unfavorable associations in SCLC, LUSC, READ, LIHC and COAD, but favorable associations in UVM. The SCLC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .010). Together, the overview and detailed table identify SCLC as the clearest survival context for DGAT2L6 RNA expression.
This table summarizes DGAT2L6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for DGAT2L6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DGAT2L6 shows higher tumor expression in THCA, KIRC, BRCA, LUAD, LIHC and KICH. The THCA box plot shows higher DGAT2L6 RNA expression in tumor versus normal tissue (log2 FC = +0.428, t-test p < 0.001).
This table shows molecular features associated with DGAT2L6 in patient tissues and cancer cell lines. In patient samples, DGAT2L6 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, DGAT2L6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
